Phase 1b Study of CS-7017 in Combination With Erlotinib in Subjects With Metastatic or Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Who Failed First-line Therapy.
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2011
At a glance
- Drugs Efatutazone; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 21 Dec 2011 Last checked against ClinicalTrials.gov record.
- 21 Dec 2011 Actual patient number added 16 according to ClinicalTrials.gov.
- 21 Dec 2011 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.